S23 SARM: Scientific Guide

S23 SARM is a pioneer in preclinical studies in androgen research. It provides unprecedented tissue selectivity, which motivates the development of models for muscle hypertrophy, bone density, and fat metabolism. Realize the potential of its research using BehemothLabz.

Get to the bottom of the S23 mechanisms, applications, and side effects to make musculoskeletal discoveries at the next level.

What is S23 SARM?

S23 is a non-steroidal SARM of the aryl propionamide class. Its initial synthesis occurred in the early 2000s to study endocrine and musculoskeletal. Its high affinity for androgen receptors (AR) is valuable to researchers because it enables tissue-selective action in preclinical models. It is possible to state that S23 has a significant anabolic effect in skeletal muscle and bone, unlike the case of traditional anabolic-androgenic steroids (AAS).

The initial research identified S23 as a potential aid in androgen therapy modeling. BehemothLabz provides S23 with HPLC purity over 99 percent, supported by third-party certificates of analysis (CoAs) for batches traceable to the lot. These characteristics allow reproducible doses in cell-based and rodent experiments.

Mechanism of Action

S23 SARM binds well with androgen receptors (AR) as a complete agonist to replicate the effects of testosterone selectively in muscle and bone and with minimal effects on the prostate. It may enter the cells, bind to AR with high affinity, and stimulate the receptor. It may influence gene expression to affect muscles (anabolic) and inhibit LH/FSH through negative feedback, thereby preventing contraceptive effects (Jones et al., 2009).

Properties Of S23 SARM

• Molecular Formula: C₁₈H₁₃ClF₄N₂O₃
• Molecular Weight: 416.76 g/mol
• PubChem ID: 168269

Key Research Applications

Preclinical models employ S23 to probe muscle hypertrophy. Here, it may induce dose-dependent increases in fiber cross-sectional area in the soleus and extensor digitorum longus muscles of orchidectomized rats. 

Bone research may reveal enhanced mineral density and trabecular architecture via micro-CT, mimicking androgen replacement without prostate hyperplasia (Wen et al., 2025).

Fat metabolism studies demonstrate S23’s role in lipolysis pathways. It may reduce epididymal fat pad mass in high-fat diet simulations through AR-mediated HSL activation. Male contraception models highlight reversible spermatogenesis suppression. 

It may reduce sperm counts while preserving proxies of libido, such as mounting behavior (Christiansen et al., 2020). S23 may be integrated into combinatorial assays with peptides such as TB-500 for wound healing or IGF-1 analogs for myogenesis (Ameline et al., 2022).

Potential Benefits in Studies

The potential benefits of S23 SARM in studies are as follows: 

Muscle Growth

S23 enhances lean body mass and body weight in castrated rats, as well as supporting protein synthesis and hypertrophy. The animal models exhibit harder, denser muscles that are better retained by the user during the process of making cuts.

Fat Reduction

It lowers the mass dose-dependently of fat in rats, and increases lipolysis (the breakdown of large fatty acid molecules into smaller ones).  Besides, it may also cause body compositional changes without reducing muscle mass in preclinical models. 

Bone Strength

S23 may influence mineral transportation and density of the bones in preclinical models. These things facilitate bone density, skeletal health, and injury prevention of bones in research models during experiments.

Safety and Considerations

Preclinical tolerability is dose-dependent and reversible. Regulatory status deems S23 unapproved by the FDA for non-research applications, with WADA listing it as a prohibited anabolic agent. Risks associated with the lab include contamination in the event of non-sterile reconstitution. 

Long-term models detect lipid changes (HDL decrease), and LFT rises (which can be reversed with cessation), which is why these changes should be monitored during multi-dose regimens (Dahleh et al., 2025).

Associated Side Effects

S23 SARM studies in lab animals show side effects that change based on dose, which help researchers understand risks:

• It may cause hormonal changes in animal models.
• It may shift blood fat and sugar in animal models.
• It may affect organs in animal models.

Legal Status

S23 SARM is not allowed for human consumption as the FDA has not yet approved it. However, researchers can use it in laboratory experiments with preclinical models.

Why BehemothLabz to Buy S23 Online

BehemothLabz delivers S23 with greater than 99% purity. It offers third-party HPLC/MS testing and discreet, temperature-controlled global shipping. BehemothLabz’s risk-free policies include DOA replacements and 100% satisfaction refunds, backed by 5-star researcher feedback.

Expert support encompasses reconstitution and stacking protocols, complements peptides such as Survodutide, and facilitates privacy-focused transactions (crypto/credit) for institutional procurement.

Conclusion

S23 advances preclinical AR research with unmatched selectivity, equipping labs for precise musculoskeletal investigations. BehemothLabz elevates experimental rigor through verified quality.

Frequently Asked Questions (FAQs)

What is S23 SARM?

S23 is an aryl propionamide-based non-steroidal SARM, which was manufactured in the early 2000s to conduct endocrine and musculoskeletal studies. It exhibits an affinity to tissue-selective action through high androgen receptor in preclinical models.

What are some of the most important applications of S23?

Muscle hypertrophy, bone density using micro-CT, fat lipolysis in high-fat model animals, and reversible spermatogenesis inhibition in contraception have been used preclinically.

What are the safety issues involved with S23 experiments?

The effects are dose-dependent and reversible; not FDA-approved for non-laboratory use; WADA-banned. It is also essential to monitor lipids and LFTs in the long-term models to prevent the risk of contamination.

Which side effects does S23 SARM have in models?

Dose-dependent in animals: hormone drops (testosterone), changes in blood fats (HDL down), small sugar increases, and organ changes (prostate gland growth or heart thickening).

Why is BehemothLabz the best choice to use in S23?

Claims more than 99 percent purity in CoA, discrete delivery, DOA money back, and specialist steps instructions to co-purify with peptides such as Survodutide.

References

1. Ameline, A., Gheddar, L., Raul, J.-S., & Kintz, P. (2022). In vitro characterization of S-23 metabolites produced by human liver microsomes, and subsequent application to urine after a controlled oral administration. Journal of pharmaceutical and biomedical analysis, 212, 114660.
2. Christiansen, A. R., Lipshultz, L. I., Hotaling, J. M., & Pastuszak, A. W. (2020). Selective androgen receptor modulators: the future of androgen therapy? Translational andrology and urology, 9(Suppl 2), S135.
3. Dahleh, M. M. M., Boeira, S. P., Segat, H. J., Guerra, G. P., & Prigol, M. (2025). A SARM a Day Keeps the Weakness Away: A Computational Approach for Selective Androgen Receptor Modulators (SARMs) and Their Interactions with Androgen Receptor and 5-Alpha Reductase Proteins. ACS omega, 10(29), 31649-31667.
4. Jones, A., Chen, J., Hwang, D. J., Miller, D. D., & Dalton, J. T. (2009). Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology, 150(1), 385-395.
5. Wen, J., Syed, B., Leapart, J., Shehabat, M., Ansari, U., Akhtar, M., Razick, D., & Pai, D. (2025). Selective androgen receptor modulators (SARMs) effects on physical performance: a systematic review of randomized controlled trials. Clinical endocrinology, 102(1), 3-27.